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Drug resistant patients undergoing epilepsy surgery have a good chance to become sensi-
tive to anticonvulsant medication, suggesting that the resected brain tissue is responsible
for drug resistance. Here, we address the question whether P-glycoprotein (Pgp) and mul-
tidrug resistance-associated proteins (MRPs) expressed in the resected tissue contribute
to drug resistance in vitro. Effects of anti-epileptic drugs [carbamazepine (CBZ), sodium
valproate, phenytoin] and two unspecific inhibitors of Pgp and MRPs [verapamil (VPM) and
probenecid (PBN)] on seizure-like events (SLEs) induced in slices from 35 hippocampal
and 35 temporal cortex specimens of altogether 51 patients (161 slices) were studied.
Although in slice preparations the blood brain barrier is not functional, we found that SLEs
predominantly persisted in the presence of anticonvulsant drugs (90%) and also in the
presence of VPM and PBN (86%). Following subsequent co-administration of anti-epileptic
drugs and drug transport inhibitors, SLEs continued in 63% of 143 slices. Drug sensitivity
in slices was recognized either as transition to recurrent epileptiform transients (30%) or
as suppression (7%), particularly by perfusion with CBZ in PBN containing solutions (43,
9%). Summarizing responses to co-administration from more than one slice per patient
revealed that suppression of seizure-like activity in all slices was only observed in 7% of
patients. Patients whose tissue was completely or partially sensitive (65%) presented with
higher seizure frequencies than those with resistant tissue (35%). However, corresponding
subgroups of patients do not differ with respect to expression rates of drug transporters.
Our results imply that parenchymal MRPs and Pgp are not responsible for drug resistance
in resected tissue.
Keywords: TLE, surgically resected tissue, seizure-like events, carbamazepine, sodium valproate, phenytoin,
verapamil, probenecid
Abbreviations: AEDs, anti-epileptic drugs; CBZ, carbamazepine; DG,
dentate gyrus; FP, extracellular field potential; [K+]o, extracellular potas-
sium concentration; MDTs, multidrug transporters, MDTIs, multidrug
transporter inhibitors; MRP, multidrug resistance-associated protein;
PBN, probenecid; Pgp, P-glycoprotein; PHT, phenytoin; RETs, recurrent
epileptiform transients; SLEs, seizure-like events; SUB, subiculum; TCx,
temporal neocortex; TLE, temporal lobe epilepsy; VPA, valproate; VPM,
verapamil.
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INTRODUCTION
Patients suffering from partial epilepsies often present with ther-
apeutic difficulties. Up to 80% of patients with temporal lobe
epilepsy (TLE) are resistant to treatment with anti-epileptic drugs
(AEDs) (1). Drug resistance may depend on the severity of disease
(2), development of tolerance (3), changes in drug targets (4–
6), network alterations (7, 8), and an open blood brain barrier
(9). As drug resistance concerns drugs with different mecha-
nisms of action, the“transporter hypothesis”received considerable
attention (10–18). This hypothesis states that drug efflux pumps
transport drug molecules out of the brain parenchyma and thereby
impede the build-up of tissue AED-concentrations sufficient for
seizure control. Multi drug transporter proteins (MDTs) include
P-glycoprotein (Pgp) and the multidrug resistance-associated pro-
teins (MRP1-5). Studies in human resected tissue of epilepsy
patients show that such proteins are up-regulated or ectopically
expressed at the blood brain barrier (19–22) and within the brain
parenchyma (13, 18, 23–25).
The aim of our present study is to find out whether Pgp
and multidrug resistance-associated proteins (MRPs) in acute
hippocampal and temporal cortex slices contribute to drug resis-
tance in the functionally blood brain barrier deprived tissue of
drug resistant patients. Our previous study of the dentate gyrus
(DG) (26) revealed that induced epileptiform activity in the DG
from drug sensitive patients and patients with extra-hippocampal
tumors was sensitive to CBZ, while similar activity of drug resistant
patients was resistant. Here, we compare effects of drugs, which
were“definitely” (phenytoin, PHT),“possibly” (metabolites of car-
bamazepine, CBZ), and “not” transported (valproate, VPA) by
human Pgp (27). Additionally, verapamil (VPM) and probenecid
(PBN) were chosen as unspecific inhibitors of Pgp and MRPs
because clinical reports described that co-application of VPM
with AEDs might restore pharmacosensitivity (28). Moreover, we
already presented evidence that the efflux pump function of Pgp
and MRPs expressed in slices from resected tissue was altered
by VPM and PBN (29). Now, we extend our electrophysiological
investigations to the subiculum (SUB) and the temporal neocor-
tex (TCx), and focus on drug effects on induced seizure-like events
(SLEs) resembling ictal discharges in intracranial recordings (30).
MATERIALS AND METHODS
Surgery specimens were obtained from 72 patients suffering from
TLE (years 2005–2009; 58 hippocampal and 52 cortical specimens)
of which 65 patients were proven drug resistant, 4 patients were
resistant but had adverse effects in at least 1 treatment strategy, and
3 patients were still not “proven” (1 year duration of epilepsy, high
seizure frequency or tumor). Pre-surgical analysis including deter-
mination of drug resistance was performed in the Epilepsy Center
of Berlin Brandenburg (Martin Holtkamp and Heinz-Joachim
Meencke) as previously described (26, 31, 32).
All patients underwent a combined resection of the temporal
pole with amygdalo-hippocampectomy (TPR+), using a cortical
approach. Surgery was a two step procedure. Between 2–2.5 cm
(dominant) and 3–3.5 cm (non-dominant) of the temporal pole
were removed first, afterwards the mesial temporal structures were
resected. The temporal pia mater covering the Sylvian vessels
remained intact. After ablation of the temporal pole, the inferior
horn was already open or could be readily opened (33). Operations
were performed by Thomas-Nicolas Lehmann, Peter Vajkoczy, and
Peter Horn in the Department of Neurosurgery, Charité.
For the purpose of the present study, 35 hippocampal and 35
temporal cortex specimens of altogether 51 patients (161 slices in
which SLEs were induced) could be included.
The study was approved by the Ethics Committee at the
Charité-Universitätsmedizin Berlin (EA125/2001, EA1/042/04)
and performed in accordance with the declaration of Helsinki.
A written informed consent was obtained from every patient
before surgery. Neighboring sections of the tissue in this study
were analyzed by the Department of Neuropathology, Charité for
diagnostic purposes.
For some patients also the tissue concentrations of OXC, CBZ,
and LTG were determined in the Department of Forensic Toxi-
cology, Institute of Forensic Medicine, Charité. CBZ, CBZ-10,11-
epoxide, oxcarbazepine, 10-hydroxy-oxcarbazepine, and lamotrig-
ine were determined by high performance liquid chromatography
with diode array detector (HPLC-DAD) described by Pragst and
colleagues (34). Reference standards for calibration of the five
compounds were obtained from LGC Promochem (Wesel, Ger-
many). Between 200 and 500 mg brain tissue were exactly weighed
and extracted with the threefold volume of acetonitrile by 2 h incu-
bation and treatment in ultrasonic bath at room temperature. After
centrifugation, the acetonitrile layer was completely separated. The
residue was thoroughly washed with the same volume acetonitrile
and centrifuged again. The extract and the washing were united
and the acetonitrile evaporated in a nitrogen stream at 40°C to
dryness. The residue was dissolved in 100µl of the mobile phase
(phosphate buffer pH 2.3/acetonitrile 63:37, v/v) and 50µl were
injected for HPLC.
TISSUE TRANSPORT, PREPARATION, AND MAINTENANCE
One or two coronal sections of 5 mm thickness were cut from the
resected temporal cortex and hippocampus, immediately trans-
ferred to cold (1–4°C) carbogenated transport solution containing
(in mM) KCl 3, NaH2PO4 1.25, glucose 10, MgSO4 2, MgCl2 2,
CaCl2 1.6, NaHCO3 21, sucrose 200, and (±) α-tocopherol 0.1
pre-dissolved in ethanol (pH 7.4, osmolality 303 mosmol/kg, 0.005
v% ethanol), and transported to the lab, as previously described
(26, 31, 32). Subsequently, the tissue was coronally dissected into
slices of 500µm thicknesses using a vibratome (Campden Instru-
ments Ltd., Leicester, UK). Slices subjected to electrophysiological
recordings were immediately transferred to interface chambers,
perfused at a rate of 1.7 ml/min with pre-warmed (34.5°C) car-
bogenated artificial cerebrospinal fluid (ACSF) containing (in
mM): NaCl 129, KCl 3, NaH2PO4 1.25, glucose 10, MgCl2 2,
CaCl2 1.6, NaHCO3 21, (±) α-tocopherol 0.03 (pH 7.4; osmo-
lality 303 mosmol/kg, 0.002 v% ethanol). Recordings commenced
4 h after preparation of slices to permit optimal recovery after
surgery and transport in solution with low sodium concentration.
ELECTROPHYSIOLOGICAL RECORDINGS AND STIMULATION
Extracellular recordings were performed in the granule cell layer
of the DG, in the pyramidal cell layer of the SUB, and in deep lay-
ers of the TCx (V–VI), 120–150µm below the surface of the slice,
using double-barreled K+-selective/reference microelectrodes as
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previously described (31). Signals were stored on a computer using
Spike2 (version 4.01, CED; Cambridge, UK) with sampling rates
of 10 kHz for field potentials (FPs, low pass filter cut-off 3 kHz)
and 100 Hz for [K+]o (low pass filter cut-off 1.6 Hz). Paired elec-
trical stimulation was performed with bipolar platinum electrodes
(wire diameter 25µm, tip distance about 50–100µm, pulse dura-
tion 0.1 ms, pulse interval 50 ms). They were positioned in the
hilus (26), in stratum radiatum of the (pro)SUB, and in the white
matter below layer VI of the TCx.
EXPERIMENTAL PROTOCOLS
Viability of slices
To exclude that drug effects were mimicked by loss of slice via-
bility, we routinely determined amplitudes of averaged responses
(n= 5) to the first response of paired stimulus-evoked FPs (every
20 s, stimulus intensities eliciting 80 or 100% of the maximal
FP amplitude) in the beginning and at the end of the experi-
ment. Experiments were accepted when the evoked signals did
not change more than 25% between the beginning and end of an
experiment.
Regionally optimized induction of seizure-like events
In the DG, hilar stimulation and elevation of potassium concen-
tration to 10–12 mM induced SLEs (26, 31) (Figure 1A). In the
SUB elevation of potassium concentration to 10–12 mM could
provoke SLEs (Figure 1B) while in the TCx 8 mM [K+] and
50µM bicuculline–methiodide were sufficient. Bicuculline was
added when [K+]o approached the plateau of equilibration (see
Figure 1C). SLEs lasted for more than 5 s (Figures 2A,C). Epilep-
tiform events shorter than 5 s were termed recurrent epileptiform
transients (RETs; Figures 2B,C). Slices in which only RETs were
observed were not included in the analysis. The differentiation
between SLEs and RETs was based on the histogram of event dura-
tions (Figure 2C) and on the relation between event duration and
event rate (not shown). The distribution of values displayed a first
minimum around 5 s and a second minimum around 15 s. How-
ever, only the first minimum was associated with a change in the
event rate. Therefore, we decided to categorize SLEs by a minimal
event duration of 5.1 s.
Treatment protocols
After induction of SLEs, slices were subjected to two different
sequential protocols denoted as“AED”followed by“AED+MDTI”
and as “MDTIs” followed by “MDTIs+AED” (Figure 2D). More-
over, a small number of control experiments have been performed
in which slices were not perfused with drugs, denoted as “No
drug”-experiments (Figure 3).
During the protocol “AED” (120 slices, 37 patients, Figure 2D,
top), one of three AEDs CBZ, 50µM,VPA, 1 mM, and PHT, 50µM
was applied for at least 20 min. Subsequently, during the protocol
“AED+MDTIs,” the MDTIs PBN (400µM) and/or VPM (40µM)
were added to the perfusion solution for another 20 min.
In order to test whether VPM and/or PBN may alter seizure-
like activity independently of their interaction with potential AED
transport, we also studied their effects on SLEs before the respec-
tive AEDs were added to the perfusate (Figure 2D, bottom).
During this protocol, referred to as “MDTIs,” PBN, and/or VPM
were applied first (41 slices, 15 patients) and then, in the protocol
“MDTIs+AED,” one of the AEDs was added to the perfusion
solution. The time schedule“MDTI”and“MDTI+AED”was sim-
ilar to that for “AED” and “AED+MDTI.” During both protocols,
the MDTIs VPM and PBN were simultaneously administered to
115 slices, PBN alone to 22 slices, and VPM alone to 22 slices.
The “No drug”-protocol (17 slices, 9 specimens, 7 patients)
lasted 80 min without drug administration (Figure 3A). This
permits to test for stability of induced activity, and to compare
drug effects to a time-matched “No drug”-group (Figure S2 in
Supplementary Material).
Drug effects were considered if at least a partial recov-
ery of epileptiform activity was achieved. All substances were
administered through the ictogenic perfusion medium.
IMMUNOHISTOCHEMISTRY OF MULTIDRUG TRANSPORT PROTEINS
Expression patterns of multidrug transporters in specimens of
drug resistant patients included in the present study have been
already published (29). In brief, we used a modified glucose
oxidase-diaminobenzidine (DAB) method (35). Tissue samples
were fixed overnight (4% PFA) and 10µm thin sections were cut
in a cryostat (Leica, Jung CM 1800) and then incubated (24 h
at 4°C) with diluted primary antibody [monoclonal antibodies:
Pgp, JSB-1 antibody (1:50); MRP1, MRPr1 antibody (1:20); MRP2,
M2III-6 antibody (1:50), Alexis Biochemicals; MRP5, M51-1 anti-
body (1:20) DCS/Signet, Hamburg, Germany]. The antibodies
were diluted in normal goat serum (10%), Triton X-100 (0.3%),
BSA, and 0.1 M PB (pH 7.4). Subsequently, slices were incubated
for 1 h in biotinylated secondary antibody (1:100), washed in AB
complex for 1 h, followed by DAB oxidation (ABC kit, Vector
Labs Burlingame, CA, USA), and then counterstained with Vector
Hematoxylin Nuclear Counterstain (Vector Labs).
Cell counting and quantification of immunohistochemistry
data were carried out semi-automatically by using the software
Kappa Image (Metreo Software, Kappa Optoelectronics) based
on the method of West and Gundersen (36). The ratio of mul-
tidrug transporter expressing cells refers to the total cell number,
determined in counterstained slices, and corrected following the
method of Abercrombie (37). The ratio values were given in per-
cent of the corresponding total cell number, averaged with respect
to each transporter type, region, and cell type per patient.
DATA ANALYSIS AND STATISTICS
Initial analysis
Initial analysis was based on the categorization of effects in a given
slice (persistence of SLE, transition of SLE to RET, or suppression
of SLE). Quantification of drug effects followed previous pro-
tocols (26). Changes of [K+]o were described (i) for the onset
of events ([K+]obase), (ii) for the event-associated maximum of
[K+]o ([K+]omax), and (iii) for the event-associated rise of [K+]o
(∆ [K+]o= [K+]omax− [K+]obase, Figure 2E). Deflections of
the FP (Figure 2F) were characterized by their event rate (n/min),
maximal slow FP amplitude [sfp (mV)], maximal peak amplitude
[peak (mV)], considering the largest negative transient, and event
duration [duration (s)]. Fluctuations with a size of <0.3 mV and
a time interval of <3 ms were excluded from the analysis.
Moreover, all activity parameters were normalized with refer-
ence to the control value, determined after a stabilization period
lasting 10–20 min, and given as remaining parameter values in
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FIGURE 1 | Induction of seizure-like events in the dentate gyrus
(DG), subiculum (SUB), and in deep layers of the temporal
neocortex (TCx). The two traces depicted for each region display
recordings of [K+]o (top) and field potential (FP) bottom. Time and
amplitude of signals are given by calibration bars on the right. Bars above
each pair of traces mark the perfusion of the ictogenic buffer solution.
(A) DG: hilar double pulse stimulation (pulse duration 0.1 ms, pulse
interval 50 ms, stimulus intensity for pulses in the range of 80% of the
maximal field potential amplitude, frequency 0.067 Hz). The stimulation
was performed before and during elevation of [K+]o to 10 mM, and had
been set off when epileptiform discharges appeared independent of
electrical pulses. (B) SUB: elevation of [K+]o to 10 mM. (C) TCx: elevation
of [K+]o to 8 mM and addition of 50µM Bicuculline when [K+]o
approximated the plateau of equilibration.
a percentage of the control value. Three normalized parameter
values (sfp, peak, and duration) were averaged as AV3 [see also
Ref. (26)]. In order to prevent statistical overweight of event rate,
normalized changes >150% were set to 150%.
In addition, a patient oriented analysis was performed, allow-
ing correlation with clinical data. All pharmacological responses
from more than one slice of the same specimen/patient were again
categorized with respect to quality and heterogeneity. In order
to relate some of our data to serum concentrations of clinically
employed drugs with different pharmacokinetic properties and
ranges of effectiveness, serum concentrations were normalized to
the maximal therapeutic serum level for each AED [set by the clin-
ical analysis, following available literature, i.e., Ref. (38)] and given
as a percentage of the maximum level.
Statistical analysis
Group data of ratio variables are displayed as mean± SEM
throughout the manuscript. Data of nominal and ordinal variables
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FIGURE 2 | Differentiation of epileptiform activities and determination of
characteristic parameters. (A,B) Traces of activity (top), single events
marked by arrow are displayed on an expanded time scale (bottom),
calibration bar for field potential amplitudes on the right. (A) Seizure-like
events (SLEs); (B) recurrent epileptiform transients (RETs); (C) histogram of
event durations for RETs and SLEs, bin width 1 s; (D) protocol sequences in
main experiments: top (n= 120): control, AED, AED+MDTIs, and Wash out
of drugs; bottom (n=41): control, MDTIs, MDTIs+AED, and Wash out of
drugs. For periods of Control and Wash out durations are given as Min and
Max, and for the drug periods as Mean (±SEM). (E) Parameters determined
for event-associated changes of extracellular potassium concentrations ([K+]o
in mM): [K+]o base in the beginning of an event, [K+]o max at the maximum
value, ∆ [K+]o rise of [K+]o; (F) parameters determined for event-associated
deviations of the field potential (FP): sfp (mV) maximum of the slow field
potential amplitude, peak (mV) maximum of the peak amplitude, and duration
(s) event duration (time from beginning of the event up to 2/3 recovery of the
sfp deflection). (E,F) Calibration bar for [K+]o and FP on the right. Abscissa in
(A,B,E,F): time in seconds (calibration bar below the FP traces).
are given as proportions of group members assigned to the
response categories. As the Shapiro–Wilk tests indicated devi-
ation from the normal distribution of values for some of the
variables, comparisons within groups and between groups were
performed using non-parametric tests (Wilcoxon, Friedman;
Mann–Whitney U, Kruskal–Wallis-H ). Proportional differences
within and between groups were evaluated applying the McNemar
and the Chi2-homogeneity test (Fisher’s exact test). All statis-
tics were calculated using the PASW statistics 18 (SPSS, Chicago,
IL, USA).
RESULTS
The present pharmacological study is based on experiments in 161
slices (35 hippocampal and 35 cortical specimens of 51 patients)
in which SLEs could be induced (2038 with Table 1). First, we
investigated pharmacosensitivity of SLEs to AEDs or MDTIs, and
then to co-administration of AEDs and MDTIs.
As shown in Figures 1 and 2A, SLEs were usually char-
acterized by a large negative FP-shift of more than 5 s dura-
tion, associated with a rise in [K+]o. Event durations var-
ied considerably (Figure 2C). In a given slice, SLEs recurred
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FIGURE 3 | Control experiments. (A) Time-matched experiments without
any drug perfusion in the dentate gyrus (DG), subiculum (SUB), and the
temporal neocortex (TCx). The recordings of [K+]o and field potential (FP)
were taken from the end of each time interval, marked above traces.
Calibration bars for amplitude and time are given on the right. (B) Time
matched remaining parameter values (percent of control values). The
remaining parameter values for event rate (eV/min), AV3 (averaged
remaining normalized parameter values for sfp, peak, and duration), [K+]o
base, and ( [K+]o show variability or slight run down but no pattern change
throughout time.
regularly after induction. In No drug experiments, the incidence
of SLEs increased with time while duration and rises in [K+]o
declined with time (Figure 3B). Also, the value of AV3 became
reduced. However, these changes were <20% in hippocampal
slices and <10% in cortical slices. Spontaneous transition of
SLEs to RETs was not observed in any of the 17 slices. SLEs
were not a priori resistant (26) (here Figure S1 in Supplementary
Material).
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Table 1 | Comparison of patient data with respect to in vitro sensitivity or resistance of SLEs to co-administration of one AED and probenecid
or/and verapamil for 40 patients providing more than one slice to the analysis.
Variables Parameters or categories Patients with
sensitive tissue
Patients with
resistant tissue
Statistics
(p-value)
Frequency of seizures per month Mean value 10.9 (26) 3.3 (13) 0.033
±SEM 2.76 0.73
Frequency of sGTCS per year Mean value 7.37 (23) 7.46 (14) 0.586
±SEM 4.42 3.19
AED treatment at operation CBZ or OXC 23.1% (26) 42.9% (14) 0.240
LTG or GBT 38.5% 35.7%
LEV 30.8% 7.1%
TPM, ZNS, or PGL 7.7% 14.3%
Brain-/serum level of AEDsa Mean value (N ) 1.5 (11) 1.05 (8) 0.322
(±SEM) 0.21 0.31
Pathology No clear pathology 26.9% (26) 28.6% (14) 1.000
Hippocampal pathology 42.3% 50.0%
Cortical pathology 19.2% 14.3%
Dual pathology 11.5% 7.1%
Outcome (ILAE) 1–2 years after operation Completely seizure free 58.3% (24) 85.8% (14) 0.564
Auras only 12.5% 0.0%
One–three seizure days/a 12.5% 7.1%
Up to 50% reductiona 8.3% 0.0%
<50% reductiona 8.3% 7.1%
MRP ne mean expression rate Mean value 21.1% (8) 17.2% (7) 0.418
±SEM 2.04 3.33
MRP as mean expression rate Mean value 32.9 (8) 25.1 (7) 0.247
±SEM 4.07 4.81
Pgp ne mean expression rate Mean value 20.3 (8) 19.1 (7) 0.908
±SEM 4.64 5.06
Pgp as mean expression rate Mean value 30.3 (8) 30.5 (7) 0.817
±SEM 3.57 4.88
All patients experienced complex partial seizures.
Explanations: (N)= number of patients given once for the whole group, but always for reduced groups (data not determined, not available, or lost). “Sensitive” to
co-administration means response in at least one slice of a patient; “resistance” denoted persistent SLEs in all slices. Corresponding mean number of slices per
patient were 4.1±0.38 and 3.1± 0.27 (p=0.255).
Categories of pathology: no clear pathology=Wyler degree 1 or 2 or discrete changes in TCx like moderate gliosis or single ectopic cells; hippocampal pathol-
ogy= hippocampal sclerosis (Wyler degree 3 or 4), or tumor; cortical pathology= contusio, atrophy, dysplasia, tumor; dual pathology=hippocampal and cortical
pathology.
aCategories of outcome: one to three seizure days per year; four seizure days per year up to 50% reduction of baseline seizure days; <50% reduction to 100%
increase of baseline seizure days.
MRP ne, MRP as, Pgp ne, Pgp as: mean expression rate for neurons or astrocytes=number of immuno-positive cells given as percent of the total number of
corresponding cells, determined and averaged for the investigated regions/specimens. The distribution of regions in the two patient groups is similar (p=1.000
Fishers exact test).
AED, anti-epileptic drugs; CBZ, carbamazepine; GBT, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PGB, pregabaline; PHT, phenytoinTPM,
topiramate; VPA, valproic acid; ZNS, zonisamide.; SEM, standard error of the mean; sGTCS, secondary generalized tonic clonic seizures.
Statistics: comparisons between the two patient-groups were performed by the Mann–Whitney-U-test (numeric variables) and Fisher’s exact test (ordinal variables).
p=error probability.
RESISTANCE OF SLEs AGAINST CARBAMAZEPINE, VALPROIC ACID,
AND PHENYTOIN EXTENDS TO CORTICAL TISSUE SLICES
Seizure-like events predominantly persisted in slices from hip-
pocampal and temporal neocortical specimens. Figures 4 and 5
give examples of drug effects on induced SLEs in the DG, SUB,
and TCx in sister slices from the same hippocampal or cortical
specimen and show that SLEs persisted in presence of CBZ, VPA,
and PHT.
The synopsis of all AED drug experiments (Figure 6) revealed
that initial SLEs (120 slices) persisted in 90% of slices, were
replaced by RETs in 8.4%, and suppressed in only 1.6%, in spite
of high AED-concentrations in the perfusion solution. Regarding
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FIGURE 4 |Typical experiments in sister-slices from the same
hippocampal specimen show persistence of SLE at the end of each
protocol sequences (control, AED, AED+MDTIs, washout). (A) In the
dentate gyrus (DG), (B) in the subiculum (SUB), S1 slice 1 with application of
CBZ, S2 slice 2 with application of VPA for both regions. The drugs applied are
described above the pairs of traces, which display [K+]o (top), and field
potential (FP) bottom. Amplitudes and time are given by calibration bars on
the right.
the different specimens,AEDs were similarly effective in modifying
SLEs in hippocampal and TCx slices (Figure 6A).
With respect to the three AEDs tested (Figure 6B), we found
in slices from hippocampal and cortical specimens that effects of
CBZ, VPA, and PHT were not significantly different, suggesting
that the efficiency of the three AEDs in the chosen concentra-
tion range is similar. Studies of drug effects on seizure parameters
(Figure 6C) also revealed that there were no significant differ-
ences between the different drugs, except for the baseline [K+]o
in slices from cortical specimens, which differed between CBZ
and PHT.
SEIZURE-LIKE ACTIVITY ALSO PERSISTS IN THE PRESENCE OF DRUG
TRANSPORT INHIBITORS
When the MDTIs VPM and/or PBN were applied first (Figure 7,
second column of traces; Figure 8, summary of 41 slices), the pro-
portion of slices with continuing SLEs amounted to 85.4%. SLEs
were never suppressed but could be transformed to RETs. Regional
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FIGURE 5 |Typical experiments in slices fromTCx-specimens. The traces
were taken at the end of all subsequent protocol sequences (control, AED,
AED+MDTIs, washout). (A) In sister-slices from the same specimen: S1
displaying resistance of SLEs against PHT and PHT+PBN+VPM; S2
illustrates resistance against PHT but transition of SLE to RET during
co-administration (PHT+PBN+VPM); (B) in another specimen also
displaying resistance of SLE against PHT but suppression of SLE during
co-administration (PHT+PBN+VPM). The drugs applied are described above
each pair of traces, which display [K+]o (top) and field potential (FP) (bottom).
Calibration bars for amplitude and time are given on the right.
differences in sensitivity to MDTIs were observed. In hippocam-
pal slices (n= 19) SLEs persisted in 100% of slices while in cortical
slices (n= 22) SLEs persisted only in 73% (p= 0.023, Fisher’s exact
test), indicating that induced activity in cortical slices was more
sensitive to MDTIs than in hippocampal slices (Figure 8A). Some
slices were investigated for singular effects of PBN (n= 11) orVPM
(n= 7). There were no proportional differences between effects of
PBN, VPM, and PBN plus VPM in hippocampal as well as corti-
cal slices (Figure 8B). Nevertheless, it should be noted that in four
temporal cortex slices in which VPM was applied alone (Figure 8B,
bottom), this drug led to transition of SLE into RETs in two slices,
an effect that was not seen with PBN. Similarly, seizure parameters
in temporal cortex slices (Figure 8C) showed that effects of VPM
were conspicuously larger than for PBN. However, the difference
could not be proven significant, due to the small number of slices
tested.
CO-ADMINISTRATION OF AEDs AND MDTIs INCREASES RESPONSES
OF SLICES
In order to find out whether co-administration of anti-seizure
drugs and MDT-inhibitors is able to reverse resistance to stan-
dard AEDs, we added PBN and/or VPM to the perfusion solution
already containing one AED (AED+MDTIs) (Figures 4 and 5,
third column of traces). Alternatively, one AED was added to the
perfusion solution already containing MDTIs (MDTIs+AED)
(Figure 7, third column of traces). As there were no differences
of co-administration effects on SLEs resistant against AEDs or
MDTIs (n= 143, p= 0.234, Fisher’s exact test), the subsamples
AED+MDTI and MDTI+AED were pooled. Together, during
combined treatment with an AED and MDTIs, SLEs persisted in
63% of slices, became converted into RETs in 30%, and suppressed
in 7%. Thus, co-application of an AED and MDTIs resulted more
frequently in transition to RET compared to slices treated with
AEDs or MDTIs alone (p< 0.001, McNemar–Bowker test). Differ-
ent from slices of cortical specimens, SLEs in hippocampal slices
continued more often (69 vs. 58%), were more often suppressed
(10.4 vs. 3.9%), and less often transformed to RET (21 vs. 38%;
Figure 9A, p= 0.042).
Concerning the combinations of AEDs and MDTIs adminis-
tered (Figure 9B), we found that SLEs were more often sensi-
tive to CBZ+PBN or CBZ+PBN+VPM (n= 54) than to all
other combined applications (n= 89, p= 0.017, Fishers exact
test). Although this was numerically true in slices from hip-
pocampal and cortical specimens, the error probability reached
significance (p= 0.022) in hippocampal specimens only. Out of
the remaining normalized parameter values event rate, AV3 and
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FIGURE 6 | Summarized effects of anti-epileptic drugs (AEDs) on
seizure-like events. Categories of drug effects, marked by different
colors, are shown on top of (A). (A) Proportional distribution of
AED-effects in hippocampal and cortical slice-groups. (B) Effects of
carbamazepine (CBZ), valproate (VPA), and phenytoin (PHT) in hippocampal
(top) and neocortical slices (bottom). (C) Corresponding averaged
remaining normalized parameter values for event rate (eV/min), AV3
(average of normalized values for sfp, peak, and duration), [K+]o base, and (
[K+]o. Ordinates: (A) percentage of slices; (C) means±SEM for remaining
percentages of control values. Signs for significant differences between
ranges of values for PHT vs. CBZ **p≤0.01. Numbers in parenthesis give
number of slices in sub-samples (A,B), or number of slices analyzed (C).
The second numbers in parenthesis of (C) display the number of slices
with reliable measurements of [K+]o.
[K+]o base significantly differed between the combinations in the
hippocampus, while [K+]o base and∆[K+]o differed in the cortex
(Figure 9C). Taken together, co-administration of one AED and
MDTIs modifies appearance of SLEs by transition to RETs but
rarely by suppression.
CO-ADMINISTRATION EXPERIMENTS REVEAL HOMOGENEOUS AND
HETEROGENEOUS RESPONSES IN SLICES OF THE SAME PATIENT
When studying the effects of CBZ in the DG of hippocampal
slices from the same patient (26), we noted that the substance
failed to suppress SLEs in one slice but was effective in another.
This may indicate differences of drug sensitivity throughout the
resected tissue, prompting investigation of multiple slices from
each patient.
One to seven slices from one specimen could be investigated
for responses of SLEs to co-administration of AEDs and MDTIs
(Figure 10A). In specimens with more than one slice (Figure S4 in
Supplementary Material), we observed different effects in 52.6%
of 19 hippocampal specimens and in 42.9% of 28 cortical speci-
mens. Consequently, categorization of the patient’s in vitro drug
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FIGURE 7 |Typical experiments with administration of probenecid (PBN)
and verapamil (VPM) followed by addition of an AED in the three regions
investigated. Substances applied are described above the pairs of traces
displaying [K+]o (top) and FP (bottom). Traces were taken at the end of each
protocol-sequence. (A,B) Synchronous recordings from one hippocampal
specimen in DG and SUB display resistance of SLE against PBN+VPM in
both regions while co-administration with VPA resulted in persistence of SLEs
in the DG and in replacement of SLEs by RETs in the SUB; (C) recordings
from a cortical specimen of another patient show transition to RET already
after application of PBN+VPM, thereby indicating seizure modifying effects
of MDTIs, which become more pronounced after co-administration with VPA.
(A,C) Amplitudes and time are given by calibration bars on the right.
response also needs consideration of heterogeneity of effects in
two or more slices of the same patient.
In summary of both specimens (Figure 10B), 40 patients pro-
vided between 2 and 7 slices to the categorization procedure. In
Figure 10B (left), responses to AED or MDTIs alone were summa-
rized. Pharmacoresistance was homogenous in 77.5% of patients.
In the remaining 22.5% of patients, sensitivity to AED or MDTIs
was found in at least one slice. In Figure 10B (right), the combined
effects of AEDs and MDTIs were summarized. The graph shows
a significantly larger proportion of patient material in which we
observed sensitivity (65%). Compared to treatment with either
AEDs or MDTIs alone, we noted a strong increase in the sensi-
tivity to co-administration of one AED and MDTIs (p= 0.001,
McNemar).
RELATIONS OF IN VITRO RESPONSE CATEGORIES TO PATIENT DATA
Patients’ with at least two slices in the analysis were compared
between in vitro “sensitive” and “resistant” groups concerning
co-administration of an AED and MDTIs as displayed in Table 1.
We also tested for age at resection, onset of epilepsy, gender,
and site of resection and found no significant differences between
the two groups (p= 0.314; 0.100, 0.739, 0.510). The two patient
groups only differ with respect to the distribution of in vivo
seizure frequencies (high for sensitive patients, low for resistant
patients) but not between their quotients of brain tissue- to serum-
concentrations of AEDs. Besides, we recognized that local tissue
concentrations of AEDs or their metabolites (in case of CBZ or
OXC) are positively correlated to corresponding serum concentra-
tions in the hippocampus (Pearson’s r = 0.764, n= 18, p< 0,001)
but not in the neocortex (r = 0.253, N = 15, p= 0.362). Also, the
local expression rates of MRPs and Pgp determined for neurons
and astrocytes in corresponding subgroups do not differ (Table 1).
These findings put doubt on a relevant role of Pgp and MRPs in
parenchymal drug resistance.
To find out, whether specimen-specific variations of patient
data may differ, we performed a separate analysis for both spec-
imens and display a corresponding table for TCx-specimens in
the Supplementary Material (Table S1 in Supplementary Mate-
rial). The error probability of 0.046 for the difference between
brain/serum concentrations of AEDs between resistant and sen-
sitive tissue in TCx-specimens was not accepted as “significant”
(SPSS 18) because of the small sample sizes and the large spread
of values in both groups.
Compared with the patient groups providing TCx-specimens
(sensitive vs. resistant) corresponding subgroups of hippocam-
pal specimens differ concerning age of onset (8.5± 2.92 years,
n= 6 vs. 22.0± 3.61 years, n= 11) and gender [sensitive patients
are mainly male (75%) resistant patients mainly female (82%,
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FIGURE 8 | Summarized effects of unspecific inhibitors of P-glycoprotein
(Pgp) and multi-drug resistance-associated proteins (MRPs). Categories
of drug effects, marked by different colors, are shown on top of (A).
(A) Proportional distribution of effects after administration of MDTIs in
hippocampal and cortical slice-groups. (B) Circles representing the
distribution of effects by probenecid (PBN), verapamil (VPM), and both PBN
and VPM in hippocampal (top) and cortical slice-groups (bottom). (C)
Corresponding averaged remaining normalized parameter values for event
rate, AV3 (average of normalized values for sfp, peak, and duration), [K+]o
base, and ( [K+]o. Ordinates: (A) percentage of slices; (C) means±SEM for
percentages of control values. Signs for significant differences between
proportional distributions *p≤0.05, or ranges of values for PBN vs.
PBN+VPM *p≤0.05. Numbers in parenthesis give number of slices in
sub-samples (A,B). The numbers in (B) also apply to (C).
p= 0.024 Fisher’s exact test)]. For subgroups in both specimens
(TCx, Hippocampus), there is no difference with respect to
pathologies (TCx p= 0.124, Hippocampus p= 0.500 for Wyler
graduation), resistance, or AED-treatment at operation.
DISCUSSION
In the present study, we investigated effects of AEDs and inhibitors
of Pgp and MRPs on artificially induced recurrent SLEs in
slices from hippocampal and cortical specimens of drug resistant
patients.
AED-RESISTANCE OF PATIENTS IS PRESERVED IN THE RESECTED
TISSUE
The vast majority of slices retained SLEs when CBZ, VPA, or PHT
was applied. In a previous study of the DG, we described that
epileptiform activity induced in slices of drug resistant patients
remained predominantly resistant to CBZ (26). Our present find-
ings on seizure-like activity support the previous statement and
we now show that this applies also to VPA or PHT. Additionally,
the results indicate that not only the DG but also the SUB and
TCx of surgically resected tissue are frequently characterized by
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FIGURE 9 | Summarized effects of one AED and MDTIs
(co-administration). Categories of drug effects, marked by different
colors, are shown on top of (A). (A) Proportions of slices showing
different effects of co-administration in hippocampal and cortical
slice-groups. (B) Proportional distributions of effects by CBZ and
PBN-containing solutions (CBZ+PBN, CBZ+PBN+VPM) and by other
combinations (CBZ+VPM, VPA+PBN, VPA+VPM, VPA+PBN+VPM,
and PHT+PBN+VPM), given in circles for hippocampal (top) and cortical
slice-groups (bottom). (C) Corresponding averaged remaining normalized
parameter values for event rate (eV/min), AV3 (average of normalized
values for sfp, peak, and duration), [K+]o base, and ( [K+]o. Ordinates:
(A) percentage of slices; (C) means±SEM for remaining percentages of
control values. Signs for significant differences between proportional
distributions of effects or between ranges of values in separate groups
(treatment or regions) *p≤0.05, **p≤0.01. Numbers in parenthesis
give number of slices in sub-samples (A,B) or number of slices analyzed
(C). The second number in parenthesis of (C) displays the corresponding
number of slices with reliable measurements of [K+]o.
pharmacoresistance of SLEs. Considering that in certain patients
the blood brain barrier is leaky (39–41), and that drug concentra-
tions in the tissue are close to plasma levels or even exceed those
(42), we used high AED-concentrations in the tissue experiments.
Despite such high concentrations, SLEs were resistant.
The present results are in line with reports on effects of AEDs
on epileptiform activity in human cortical slices, focused on short
recurrent discharges induced by lowering [Mg2+] in the perfusion
medium. In a study by Oby and colleagues, application of 50µM
CBZ or PHT resulted in a slight modification of the repetition
rate and a decline of the integrated amplitude of short recurrent
epileptiform discharges (43). Levetiracetam in human temporal
cortex slices did not affect spontaneous sharp waves or Mg2+-
free induced epileptiform FPs (44). The agreement of results from
several studies using different induction protocols suggests that
pharmacological investigations aiming at detection of new suitable
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FIGURE 10 | Summarized responses to co-administration of AED and
MDTIs in specimens and patients. (A) Effects in slices from
hippocampal (top) and cortical (bottom) specimens, ordered by patient
number for determination of the patient’s response category. Patients
providing both, hippocampal and cortical specimens are marked by
dotted lines on top of columns in (B). (B) Proportional distribution of
different response categories for patients with at least two slices in the
analysis. In order to evaluate the changes by co-administration, we
present two circles, one for responses to AED or MDTIs alone (pooled
sample, left) and another one for responses to co-administration (right).
The lines around circles indicate subgroups of patients who were
“sensitive” to the respective treatment in at least one slice. Numbers in
parenthesis denote the number of slices/specimens (A) or the number
of patients (B).
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drugs for drug resistant patients are also possible in centers where
only neocortical tissue is available.
VERAPAMIL AND PROBENECID PARTIALLY MODIFY INDUCED
EPILEPTIFORM ACTIVITY IN CORTICAL SLICES
Verapamil and PBN were used as broad spectrum drug transport
inhibitors. However, these agents also have unspecific anticonvul-
sant effects. Indeed, VPM and PBN, administered in the absence
of AEDs, led to transformation of SLEs into RETs in 30% of TCx
slices, which was never observed in the DG or SUB. This effect
might be related to direct anticonvulsant effects.
Verapamil, known as an organic L-type calcium channel antag-
onist, was shown to exert anticonvulsant effects in a number of
experimental models of epilepsy (45–49). Even in human tis-
sue, VPM reduced spontaneous FP transients and low Mg2+ and
bicuculline-induced epileptiform activity (50, 51).
Less is known about anticonvulsant effects of PBN. PBN might
affect release of ATP and (conversion to) adenosine (52) as well
as regulatory processes within a complex metabolic chain provid-
ing for neuroprotective effects of the NMDA-receptor inhibitor
kynurenic acid and also the neurotoxic quinolinic acid (53, 54).
Substances such as adenosine (55–59), taurine (60, 61), and
kynurenic acid (54) are known to exert anticonvulsant effects.
More recently, it was suggested that PBN blocks pannexin hemi
channels (62), which might contribute to seizure activity when
opened (63). Thus, our finding that PBN and VPM administered
before application of CBZ, VPA, or PHT can convert SLEs into
RETs suggests that any of those agents or their combination sup-
port the effect of AEDs and therefore might indicate a rational
basis for multi drug treatment in some instances.
IS THERE EVIDENCE FOR A CONTRIBUTION OF Pgp OR MRPs TO DRUG
RESISTANCE?
Clinical data exist, which show that VPM can sometimes be used
as an additive drug in the treatment of refractory epilepsy (28), in
severe myoclonic epilepsy in infancy (64), and in the treatment of
pharmacoresistant status epilepticus (65–67).
In the present study, co-administration of one AED and MDTIs
in slices resulted more often in a transition of SLEs to RETs than
administration of AEDs or MDTIs alone. However, full suppres-
sion of SLEs suggesting reversal of drug resistance was rarely
observed. This would be in agreement with a previous report of
Rivers and colleagues who could not assess reversion of the drug
resistance phenotype and possible interactions with ABC-drug
transporters for any of the AEDs used in our study (68).
We showed that CBZ co-applied with PBN− or PBN+VPM
containing solutions was more effective than other combinations,
particularly in the hippocampus. The finding that in the hip-
pocampus weak or no effects were noted in presence of AEDs or
MDTIs alone but strong effects during co-administration of CBZ
and MDTIs might be a sign for interaction of metabolites of CBZ
with MRPs in the hippocampus. However, our previous results on
slices of a subgroup of similar patients showed that efflux pump
function is preserved in both specimens (57% of temporal cortex
slices and 60% of hippocampal slices). Moreover, corresponding
sub-samples of slices did not differ with respect to expression of
MDTs in the TCx and hippocampus (29).
We further calculated tissue-serum quotients of AED-levels in
a subset of patients and found that they were only rarely and
not homogeneously low. Although there are no data about the
unbound fraction of AEDs in the present study, the value for total
levels of AEDs in the tissue told us that AEDs reached the brain
tissue in both subgroups, patients with in vitro sensitive as well as
resistant tissue, at least in the hippocampus.
Provided that PHT is a substrate of Pgp but not VPA (69–71),
blocking the transport might augment effects of PHT. However,
a selective augmentation for PHT and MDTIs was not observed.
Metabolites of CBZ with anticonvulsant or convulsant properties
[Ref. (72) for a convulsant metabolite of CBZ] may be sub-
ject to drug efflux pump transport (73, 74). Therefore, it is of
interest that we detected more frequently and stronger effects of
CBZ when co-administered with PBN or PBN and VPM than
for VPA and PHT in corresponding experimental conditions. In
contrast, Luna-Tortos and colleagues reported that there was no
PBN- or MK571-inhibitable transport of CBZ, VPA, and PHT in
experiments on cell lines transfected with human MRPs (75).
Taken together, it seems to be less likely that our results on
modification of SLEs can be ascribed to increased drug concen-
tration at cellular targets of AEDs but rather are the consequence
of combined drug effects at several anti-seizure targets.
HETEROGENEITY OF IN VITRO DRUG EFFECTS
Here, we show for the first time that slices of the same patient
display different responses of SLEs to co-administration of one
AED and MDTIs. This might be caused by different consequences
of surgical handling and slicing in the laboratory as well as by
different pathological changes in individual slices of the same spec-
imen. To clarify the reasons for heterogeneity of pharmacological
responses in slices of the same specimen a new study of differ-
ential morphological, biochemical, and immunological properties
in “responding” and “non-responding” slices is ongoing. When
responses of hippocampal and cortical specimens were catego-
rized for treatment with AED or MDTIs, we noted mixed effects
(resistance and pattern change) in 19% of patients. Such mixed
effects increased to 54% during co-administration of one AED
and MDTIs, and homogeneous suppression also increased from
0 to 7% of 41 patients. Nevertheless, the finding that there were
no differences between the response categories regarding MRP-
and Pgp local expression rates or tissue/serum quotients of AED-
concentrations suggest a rather marginal contribution of MDTs to
drug resistance in tissue without a functional blood brain barrier.
LIMITATIONS
1. We did not observe spontaneous SLEs in human tissue slices
and needed induction of seizure-like activity by modification of
the electrolyte supplying the slices. The fact that spontaneous
seizures were never detected presumably results from inter-
ruption of essential connectivity by surgery and preparation
of slices. Even if the tissue would be capable to generate SLEs
spontaneously, the low incidence of seizures in TLE patients
would make it unlikely that we observed spontaneous seizures
during the possible observation time.
2. Our study does not address the mechanisms underlying dif-
ferent vulnerability of hippocampal and neocortical tissue to
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modifications in potassium concentration. With respect to the
requirement of bicuculline for induction of SLEs in slices
of cortical specimens it might be of advantage to synchro-
nously investigate changes of inter-neurons concerning mor-
phology and molecular biology of their afferent connections
and synaptic transmission to target cells.
3. It is presently not known whether resistance of induced SLEs
in slices reflects resistance of spontaneous seizures of patients
and if potential mechanisms of multidrug resistance found in
this model system can be translated to the clinical setting of
refractory epilepsy. None of the available models of pharma-
coresistance so far is clinically validated. There are no drugs
available, which are more effective in such models than the clin-
ically employed AEDs. This is also true for the induced SLEs in
this study. However, when potential seizure controlling drugs
are effective ex vivo in human tissue, this might encourage fur-
ther development and eventually testing in pharmacoresistant
patients.
4. The non-selectivity of PBN and VPM with respect to inhibition
of drug transport provides no clear argument against the design
of our co-administration experiments. We found similar effects
of adding MK 571 or PBN to VPA and VPM in the same slice
(Figure S3 in Supplementary Material). Additionally, our find-
ings that VPM and PBN altered drug efflux pump function in
slices (29) support the use of VPM and PBN as drug transport
inhibitors.
CONCLUSION
The results of the present study indicate that SLEs in resected
human temporal cortex and hippocampus are predominantly
resistant to CBZ, VPA, and PHT as well as to drug transport
inhibitors like VPM and PBN.
Complete suppression of seizure-like activity was rarely
observed after co-administration of an AED with PBN and VPM,
suggesting that drug resistance in slices is not reversed by inhi-
bition of drug transport with PBN and VPM. This suggestion is
supported by the fact that patients with in vitro sensitive tissue do
not differ from patients with in vitro resistant tissue concerning
expression rates of Pgp and MRPs or quotients of tissue/serum
levels of anticonvulsants.
Co-administration of an AED with PBN and VPM in vitro
increased the efficiency in modifying induced seizures (SLEs),
rather by adding several anticonvulsant effects than by interaction
with drug transport.
The heterogeneity of drug effects in different slices of the same
patient remains to be elucidated.
Provided that the resistance of induced SLEs as well as the het-
erogeneity of drug effects reflect rather disease dependent than
methodological consequences, our findings suggest that human
tissue slices can be used for the evaluation of new drugs for patients
with drug refractory epilepsy, i.e., by performing experimental
multi-center studies.
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